NOVARTIS AG files 6-K

Novartis announced that its investigational therapy del-brax met the primary and key secondary endpoints in the biomarker cohort of the FORTITUDE Phase I/II study for facioscapulohumeral muscular dystrophy (FSHD), indicating potential as the first disease-modifying treatment for the condition. The company plans to engage global regulatory authorities on these Phase I/II data as a Phase III study is currently enrolling.